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ABSTRACT: Covalent conjugates of multiple nutrients often 
exhibit greater biological activities than each individual nu-
trient and more predictable safety profiles than completely 
unnatural chemical entities. Here we report the construction 
and application of a focused chemical library of 308 covalent 
conjugates of a variety of small-molecule nutrients. Screen-
ing of the library with a reporter gene of sterol regulatory 
element-binding protein (SREBP), a master regulator of 
mammalian lipogenesis, led to the discovery of a conjugate of 
docosahexaenoic acid (DHA), glucosamine, and amino acids 
as an inhibitor of SREBP (molecule 1, DHG). Mechanistic 
analyses indicate that molecule 1 impairs the SREBP activity 
by inhibiting glucose transporters and thereby activating 
AMP-activated protein kinase (AMPK). Oral administration 
of molecule 1 suppressed the intestinal absorption of glucose 
in mice. These results suggest that such synthetic libraries of 
nutrient conjugates serve as a source of novel chemical tools 
and pharmaceutical seeds that modulate energy metabolism. 
INTRODUCTION 
Carbohydrates, lipids, amino acids, and vitamins consti-
tute some of the nutrients essential for the life of an organ-
ism.  On the other hand, there exist a number of pharmaceu-
ticals and functional foods that consist of covalently conju-
gated multiple nutrients. For example, tocopherol nicotinate, 
a clinically used lipid antioxidant (Figure S1A), 1 is a synthetic 
conjugate of vitamins E and B3. Another example is a conju-
gate of vitamin C and glucose, AA-2G (Figure S1B).2 This 
long-acting prodrug, used as a component of cosmetics and 
supplements, is enzymatically metabolized to gradually re-
lease vitamin C and glucose. The nutrient conjugates exem-
plified by these two examples tend to show greater potency 
than a mixture of the individual components and more pre-
dictable safety profiles than completely unnatural chemical 
entities.  
A large number of nutrient conjugates are also naturally 
occurring in organisms. For example, NA-Gly, a conjugate of 
arachidonic acid and glycine (Figure S1C), plays distinct roles 
from those of the parental nutrients, including inhibition of 
T-type calcium channel and fatty acid amide hydrolase.3 
These considerations led to the hypothesis that combinatori-
al chemical synthesis of covalent nutrient conjugates pro-
duces a focused chemical library that potentially contain 
unique, relatively safe biologically active molecules.  
RESULTS AND DISCUSSION 
To construct a library of nutrient conjugates, we em-
ployed Ugi reaction, a four-component reaction involving a 
ketone or aldehyde, an amine, an isocyanide, and a carbox-
ylic acid to form a bis-amide4 (Scheme 1). The use of Ugi re-
action for chemical library construction is not new: a number 
of other studies have generated chemical libraries through 
the multi-component one-pot reaction.5,6 Nevertheless, it has 
never been used for constructing a library of nutrient conju-
gates. Reaction components were chosen mainly from nutri-
ents or their precursors that are often included in multi- 
vitamin supplements: 20 fatty acids and 3 vitamins as car-
boxylic acid components; glucosamine and a vitamin, two 
monoamines, 4 amino acids, and two biologically active pep-
tides (VPP7 and carnosine8,9) as amine components, 3 alde-
 hydes corresponding to glycine, valine, phenylalanine; and 
ethyl isocyanoacetate to form a glycine ester terminus. Com-
binatorial parallel Ugi reactions of these components yielded 
308 nutrient conjugates. Purities of the desired products 
were checked by LC-MS, and reaction yields ranged from 2.7-
83% (Table S1). 
Scheme 1. Construction of Nutrient Oriented Chemi-
cal Library  
 
One biological activity expected from these nutrient con-
jugates was the modulation of energy metabolism in mam-
malian cells. For proof of concept, we screened the library by 
using a reporter gene of sterol regulatory element-binding 
protein (SREBP), a master transcription factor of lipogene-
sis.10 SREBP is positioned in the far downstream of mamma-
lian energy metabolism pathways,11 so that the SREBP report-
er gene activity serves as an indicator for a myriad of cellular 
metabolic alterations. Chinese hamster ovary (CHO)-K1 cells 
were transfected with the SREBP reporter gene in which the 
expression of firefly luciferase is controlled by three SREBP 
binding sites.  A constitutively active β-Gal reporter gene was 
also co-transfected for normalization purposes.12 We con-
ducted initial screening at 10 μM of the compounds and se-
lected screening hits that exhibited SREBP inhibition higher 
than that of 25-hydoroxycholesterol (HC), a known endoge-
nous inhibitor of SREBP, after 24-h incubation (Table S1). 
Repeated experiments identified 5 conjugates that showed 
clear dose-dependence (Figure S2). Of the five conjugates, 
three molecules were structurally analogous (Figure S2), and 
the most potent molecule was molecule 1, which is composed 
of DHA, glucosamine, and phenylalanine-glycine dipeptide 
(Figure 1A). We therefore focused our efforts on molecule 1 
(also referred to as DHG) for further investigations. 
 
Figure 1. Chemical structure of molecule 1 and its SREBP in-
hibitory activity.  (A) Chemical structure of molecule 1 
(DHG). (B) Dose response curve for molecule 1. Molecule 1 
suppressed the ability of endogenous SREBPs to activate 
transcription of a luciferase reporter gene. The IC50 value was 
estimated to be 5.6 M from a four-parameter logistic model 
fitting curve (Image J). The -galactosidase activity showed 
no detectable change in the tested concentrations of mole-
cule 1. (C) Chemical structures of dipeptide 2 and two-
components conjugates (3-5). (D) SREBP inhibitory activities 
of molecules 1-5. Luciferase activities were measured at a 
concentration of 10 M after 24-h incubation. Each single 
component (DHA, glucosamine [GlucN], and dipeptide 2) or 
their mixture exhibited weaker activity than molecule 1. The 
two-components conjugates (3-5) also displayed weaker ac-
tivities than molecule 1. 
 The IC50 value of molecule 1 for the SREBP reporter gene 
was estimated to be 5.6 μM, while its effects on the β-Gal 
reporter gene up to 30 μM were undetectable, indicating that 
24-hour incubation with molecule 1 has no detectable cyto-
toxicity up to 30 μM (Figure 1B). We examined the ability of 
each of the components (DHA, glucosamine, and phenylala-
nine-glycine dipeptide 2) to inhibit SREBP at 10 μM (Figure 
1D). Although DHA was found to be slightly active, as previ-
ously reported,13 the other two were essentially inactive. Im-
portantly, the activity of a mixture of the three components 
was as low as that of DHA. We chemically synthesized three 
partial structures of molecule 1 by combining two of the 
components (molecules 3-5) (Figure 1C). Although molecules 
3 and 5, which contain DHA, exhibited activity similar to that 
of DHA, the partial structures failed to exert clear inhibitory 
activity at 10 M (Figure 1D). These results indicate that co-
valent conjugation of all the three components is required 
for the potent activity of molecule 1.  
To gain insights into the mechanism of action, we exam-
ined the status of an SREBP protein upon treatment with 
molecule 1. Newly synthesized SREBPs are localized on the 
endoplasmic reticulum (ER) membrane, where they bind to 
SREBP cleavage-activating protein (SCAP), an escort protein 
of SREBPs.14,15 At low levels of cellular sterol, the SREBP-
SCAP complex is transported from the ER to the Golgi appa-
ratus, where SREBPs are cleaved sequentially by site-1 prote-
ase (S1P) and site-2 protease (S2P), liberating the NH2-
terminal transcription factor domain of SREBPs.10,16 The ma-
ture form translocates to the nucleus, where it activates lipo-
genic genes.10 The activation of SREBPs is tightly regulated 
by a negative feedback loop in which cholesterol and 25-
hydroxycholesterol (25-HC) bind to SCAP and Insigs (ER 
anchor proteins), respectively, resulting in retention of the 
SREBP-SCAP complex in the ER.17,18 Western blot analysis of 
SREBP-2 in CHO-K1 cells indicates that molecule 1 decreases 
the amounts of the mature form and accumulates the pre-
cursor form until 6 h of incubation, much like 25-HC  (Figure 
2A). However, prolonged treatment with molecule 1 de-
creased the amounts of the precursor, whereas 25-HC did not 
(Figure 2A). Since SREBP proteins are unstable once released 
from SCAP,19,20,21 molecule 1 is likely to inhibit the activation 
process of SREBP-2 posterior to its release from SCAP unlike 
25-HC does. 
The relatively large structure of molecule 1 (molecular 
weight: 722.92) prompted us to estimate its membrane per-
meability. Parallel artificial membrane permeability assay 
(PAMPA) showed a limited permeability of molecule 1 
through a lipid-infused artificial membrane (Mean Papp: 1.19 
x 10-6 cm/s). The low membrane permeability increased the 
possibility that molecule 1 either targets extracellular pro-
teins or is actively transported into cells. A number of studies 
have shown that covalent conjugations of nutrients and vit-
amins increases active transport of pharmaceuticals.22,23 
The presence of a glucose unit in molecule 1 encouraged 
us to examine the effects of glucose transporter inhibitors on 
the activity of molecule 1. Glucose is known to be transport-
ed by two classes of transporters: glucose transporters 
(GLUTs) or sodium-glucose transport proteins (SGLTs). To 
our surprise, western blot analyses of SREBP-2 in CHO-K1 
cells revealed that co-incubation with phloretin, a repre-
sentative GLUT inhibitor, enhanced the ability of molecule 1 
to decrease the protein levels of SREBP-2, while that with 
phlorizin, a representative SGLT inhibitor, failed to do so 
(Figure 2B). Importantly, phloretin alone, but not phlorizin, 
decreased the amounts of both the mature and precursor 
forms of SREBP-2 in CHO-K1 cells, although not as potently 
as molecule 1 did (Figure 2B). These results imply that mole-
cule 1 impairs SREBP-2 activation by inhibiting GLUTs rather 
than by being transported through GLUTs.  
 
Figure 2. Mechanistic analysis of molecule 1 (A) Effects of 
molecule 1 on the SREBP-2 maturation. CHO-K1 cells were 
treated with molecule 1 (10 µM) or 25-hydroxycholesterol (5 
µM) for varied lengths of time, and the cell lysates were ana-
lyzed by western blots with an SREBP-2 antibody. Positions 
of precursor and mature forms of SREBP-2 are indicated on 
the right. (B) Effects of transporter inhibitors on the SREBP-2 
maturation. Glucose transporter (GLUT) inhibitor phloretin 
(100 µM) or sodium-glucose transport protein (SGLT) inhibi-
tor phlorizin (100 µM) were added to the culture medium of 
CHO-K1 cells in the presence or absence of molecule 1 (10 
µM). After 24-hour incubation, the cell lysates were analyzed 
by western blots with an SREBP-2 antibody. Positions of pre-
cursor and mature forms of SREBP-2 are indicated on the 
right. (C) Inhibition of cellular glucose uptake by molecule 1. 
Uptake of fluorescently-labeled glucose analog 2-NBDG was 
measured with human Caco-2 cells.  The cells were treated 
simultaneously with NBDG (200 µM) and varied concentra-
tions of molecule 1 (3-30 µM), molecule 3 (3-30 µM), or posi-
tive control phloretin (100-500 µM). After extensive wash, 
fluorescence of the cells was measured with a fluorescence 
plate reader (excitation: 490 nm; emission: 530 nm). (D) 
AMPK activation by molecule 1. Hepa 1-6 cells were treated 
with molecule 1 (10 µM), phloretin (100 µM), or molecule 3 
(10 µM), and the cell lysates were analyzed by western blots 
with an antibody specific for phosphor-Thr172 AMPK. It is 
evident that molecule 1 activates AMPK phosphorylation just 
like phloretin. 
To support the hypothesis, we next examined the ability 
of molecule 1 to block glucose uptake of differentiated Caco-
2 cells, a human intestinal cell line that expresses GLUTs, 
especially GLUT224 Molecule 1 blocked cellular uptake of the 
fluorescently-labeled glucose analog 2-NBDG (2-(N-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose)25,26 
in a dose-dependent manner, whereas a control molecule 
that lacks the sugar moiety of molecule 1 (molecule 3) had 
little effects. No apparent cell death was observed during the 
course of the 3-hour study. The inhibitory activity of mole-
 cule 1 at 10 μM was comparable to that of high concentra-
tions of phloretin (Figure 2C). 
There are four major glucose transporters in human cells: 
GLUT1-4 (SLC2A1-4). Overexpression of each glucose trans-
porter increased glucose uptake in HEK293 cells, and the 
ability of molecule 1 to cancel the increase was examined. 
The results (Figure S3) suggest that molecule 1 exhibits broad 
selectivity to glucose transporters. Stronger inhibition was 
observed for GLUT2-4 than for GLUT1, which is consistent 
with the results of Caco-2 cells whose major glucose trans-
porter is GLUT2.24,27     
Inhibition of cellular glucose uptake usually results in a 
shortage of intracellular energy, leading to the activation of 
AMP-activated protein kinase (AMPK), a sensor of cellular 
energy and nutrient status.28,29 It has also been demonstrated 
that the activation of AMPK induces phosphorylation of 
SREBPs to block the nuclear translocation of SREBPs, so that 
the cells terminate lipogenesis upon limited availability of 
cellular energy.30 Western blot analyses with an antibody 
against phospho-AMPK indicate that 3-hour treatment of 
Hepa1-6 cells with molecule 1 (10 μM) induced the Thr172 
phosphorylation of AMPK as much as that with phloretin 
(100 μM) did, whereas three partial structures of molecule 1 
(molecules 3-5) failed to induce the phosphorylation of 
AMPK (Figure 2D and Figure S4). At this moment, we cannot 
rule out the possibility that molecule 1 has SREBP-inhibition 
mechanisms other than the energy depleting activity. None-
theless, the inhibition of glucose transporters and the subse-
quent activation of AMPK provides one possible explanation 
for the observed SREBP inhibition in the cultured cells.  
 
Figure 3. Glucose uptake in fasted mice. (A) Oral co-
administration of molecule 1 and glucose. Molecule 1 (6.25 
mol) or molecule 3 (6.25 mol) was orally co-administrated 
into fasted mice (n=3) with glucose (12.5 mg) in water (250 
L). (B) Pretreatment with molecule 1 prior to glucose oral 
administration. Molecule 1 (6.25 mol) or molecule 3 (6.25 
mol) was orally administrated into fasted mice (n=3) 10-min 
before oral administration of glucose (12.5 mg) in water (250 
L). Blood samples were collected at indicated time points 
and analyzed by a blood glucose self-monitoring kit. 
The glucose uptake inhibitory activity in Caco-2 cells and 
the limited cell permeability of molecule 1 encouraged us to 
examine the effects of orally administered molecule 1 on in-
testinal absorption of glucose in mice. Mice were fasted for 
24-hours prior to oral administration of a glucose solution 
comparable to typical sweetened beverage products. Oral co-
administration of molecule 1 (Figure 3A) or its administra-
tion 10 min prior to the glucose administration (Figure 3B) 
significantly suppressed the increase of blood glucose levels. 
In contrast, molecule 3, which is devoid of the glucose seg-
ment, exhibited no detectable effects. We found no apparent 
toxicity of molecule 1 in mice such as diarrhea during the 
course of the experiments. Although the suppression of 
blood glucose levels may not necessarily due to the inhibi-
tion of glucose transporters, these animal effects were con-
sistent with the glucose uptake inhibition observed in the 
cultured cells. 
In the present study, a chemical library of 308 covalent 
conjugates of multiple nutrients and vitamins led to the dis-
covery of molecule 1 as a new inhibitor of glucose uptake in 
vitro and in vivo. It remains unclear how this particular nu-
trient conjugate blocks glucose uptake. Perhaps the glucose 
moiety of molecule 1 may be recognized by glucose trans-
porters, but the hydrophobic DHA tail and bulky dipeptide 
segment could prevent the transport of the entire molecule.  
Close inspection of the screening results indicates the 
two major structural requirements for the activity. First, the 
molecule 1 analogs with unsaturated fatty acids tend to be 
more potent than those with saturated fatty acids (Figure S5). 
Covalent conjugates of unsaturated fatty acids and glycine 
have been reported to block glycine transporters.31Although 
it remains unknown why unsaturated fatty acids work better 
than saturated fatty acids, covalent conjugation of unsaturat-
ed fatty acids with nutrients might provide a general strategy 
to designing nutrient transporter inhibitors.  
Second, replacement of the phenylalanine segment with 
glycine or valine impairs the activity (Figure S6). A number 
of glucose transporter inhibitors have been documented in 
the literature.32 One recently reported GLUT1 inhibitor has a 
peptidic structure containing a fluorinated phenylalanine 
component and two other phenyl groups, all of which inter-
act extensively with the transporter near the glucose-binding 
poket.33 The phenylalanine segment of molecule 1 might sim-
ilarly assist the interaction of molecule 1 in the glucose-
binding pocket.  
In conclusion, we report the construction of a focused 
chemical library of 308 covalent conjugates of a variety of 
small-molecule nutrients. The utility of the library was 
demonstrated by isolation of new SREBP inhibitors that tar-
get glucose transporters. The nutrient conjugates are ex-
pected to exert a myriad of biological activities due to the 
fact that each nutrient component per se plays certain physi-
ological roles. On the other hand, it also means that such a 
conjugate might display multiple distinct activities. We 
checked whether molecule 1 modulates the activity of LXR, a 
nuclear receptor that controls the expression of SREBP in 
response to a number of nutrients including 25-HC and glu-
cose.34,35 Reporter gene assays indicate that molecule 1 exhib-
ited no significant effects on LXR (Figure S7).  Effects of mol-
ecule 1 on the enzymatic activity of hexokinase, another glu-
cose-binding protein, were also examined in vitro and found 
to be negligible (Figure S8). Although we cannot conclude 
 that molecule 1 is truly specific to glucose transporters, such 
covalent conjugations modulate the selectivity of the nutri-
ents to their original targets.  Expansion of nutrient-based 
chemical libraries would provide invaluable source of novel 
chemical tools and pharmaceutical seeds that modulate en-
ergy metabolism.  
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